ClinicalTrials.gg
CompletedNCT01235936Updated Jul 1, 2022Results posted

Safety and Efficacy Study for AKB-6548 in Participants With Chronic Kidney Disease and Anemia

A Phase 2 interventional study of AKB-6548 in Anemia and Kidney Disease, sponsored by Akebia Therapeutics. Completed at 2 sites in United States. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2022-07-01.

Sponsored by Akebia Therapeutics · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies testing vadadustat in Anemia — 1 open to participants now, 1 under way, none of them phase 3. vadadustat · Anemia.

Enrollment
22nd of 27
10 · median 60
Started
2010
the only one that year
Phase 2
8 of 27
none open now
Registered
1st of 27
by date
Lead sponsor
21 of 27
Akebia Therapeutics

Among the 27 studies testing vadadustat in Anemia, this one is the 22nd largest by enrollment, is the only one that started in 2010, is one of 8 in phase 2, and was the 1st registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

Browse Anemia studies →

Open to participants now

1 of the 27 studies testing vadadustat in Anemia is open now. Recruiting first, the newest first:

About vadadustat

vadadustat: first FDA approval 2024 (VAFSEO), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing vadadustat in Anemia, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, pharmacodynamics and pharmacokinetics of repeat doses of orally administered AKB-6548 in pre-dialysis participants with anemia.

03

Conditions studied

  • Anemia
  • Kidney Disease

Keywords

  • anemia
  • chronic kidney disease
  • CKD
  • chronic renal insufficiency
  • renal impairment
  • erythropoietin
  • safety
  • efficacy
  • tolerability
  • pharmacokinetics
04

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • 18 to 79 years of age, inclusive
  • Chronic Kidney Disease Stage 3 or Stage 4
  • (Hgb) \< 10.5 g/dl
  • TSAT > 20% and CBC indicating normocytic red blood cell morphology

Key Exclusion Criteria:

  • > 40
  • Red blood cell transfusion within 12 weeks.
  • Androgen therapy within the previous 21 days prior to study dosing
  • Therapy with any approved or experimental erythropoiesis stimulating agent (ESA) within the 10 weeks prior to the Screening visit
  • Participants meeting the criteria of ESA resistance within the previous 4 months
  • Individual doses of intravenous iron of 250 mg or larger within the past 21 days
  • or ALT >1.8x .
  • Alkaline phosphatase >2x ULN.
  • Total >1.5x ULN.
  • Uncontrolled hypertension
  • Class III or IV congestive heart failure
  • Myocardial infarction, acute coronary syndrome, or stroke within 6 months prior to dosing
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    AKB-6548

    Drug: AKB-6548

Interventions

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in Hemoglobin (Hgb) on Day 29

    Blood samples were collected to assess Hgb. Baseline Hgb was defined as the average of the 2 samples obtained prior to dosing (Pre-Baseline and Baseline). A positive change from baseline indicates that hemoglobin concentration increased.

    Time frame: Baseline; Day 29

Secondary outcomes

  1. Mean Change From Baseline in Hematocrit on Day 29

    Blood samples were collected to assess hematocrit. A positive change from baseline indicates hematocrit concentration increased.

    Time frame: Baseline; Day 29

  2. Mean Change From Baseline in Total Red Blood Cell (RBC) Count on Day 29

    Blood samples were collected to assess RBC count. Baseline RBC count was defined as the average of the 2 samples obtained prior to dosing (Pre-Baseline and Baseline). A positive change from baseline indicates RBC count increased.

    Time frame: Baseline; Day 29

  3. Mean Change From Baseline in Absolute Reticulocyte Count on Day 29

    Blood samples were collected to assess reticulocyte count. Baseline absolute reticulocyte count was defined as the average of the 3 reticulocyte counts obtained prior to dosing (Screening, Pre- Baseline, and Baseline). A positive change from baseline indicates absolute reticulocyte count increased.

    Time frame: Baseline; Day 29

  4. Mean Change From Baseline in Reticulocyte Hemoglobin (Hgb) Content on Day 29

    Blood samples were collected to assess reticulocyte Hgb. Baseline Hgb was defined as the average of the 2 samples obtained prior to dosing (Pre-Baseline and Baseline). A positive change from baseline indicates reticulocyte Hgb content increased.

    Time frame: Baseline; Day 29

  5. Number of Participants With Absolute Change From Baseline in Hemoglobin (Hgb) at Day 29

    Blood samples were collected to assess Hgb. Baseline Hgb was defined as the average of the 2 samples obtained prior to dosing (Pre-Baseline and Baseline).

    Time frame: Day 29

  6. Number of Participants With the Percentage Change From Baseline in Hemoglobin (Hgb) at Day 29

    Blood samples were collected to assess Hgb. Baseline Hgb was defined as the average of the 2 samples obtained prior to dosing (Pre-Baseline and Baseline).

    Time frame: Day 29

  7. Number of Participants With Percentage Change From Baseline in Hematocrit at Day 29

    Blood samples were collected to assess hematocrit.

    Time frame: Day 29

  8. Number of Participants With Percentage Change From Baseline in Red Blood Cell (RBC) Count at Day 29

    Blood samples were collected to assess RBC count. Baseline RBC count was defined as the average of the 2 samples obtained prior to dosing (Pre-Baseline and Baseline).

    Time frame: Day 29

  9. Number of Participants With Change From Baseline in Absolute Reticulocyte Count at Day 29

    Blood samples were collected to assess reticulocyte count. Baseline absolute reticulocyte count was defined as the average of the 3 reticulocyte counts obtained prior to dosing (Screening, Pre- Baseline, and Baseline).

    Time frame: Day 29

  10. Change From Baseline in Ferritin on Day 29

    Blood samples were collected to assess ferritin. A positive change from baseline indicates ferritin content increased.

    Time frame: Baseline; Day 29

  11. Change From Baseline in Iron on Day 29

    Blood samples were collected to assess iron. A positive change from baseline indicates iron content increased.

    Time frame: Baseline; Day 29

  12. Change From Baseline in Total Iron Binding Capacity on Day 29

    Blood samples were collected to assess total iron binding capacity. A positive change from baseline indicates total iron binding capacity increased.

    Time frame: Baseline; Day 29

  13. Change From Baseline in Transferrin Saturation on Day 29

    Blood samples were collected to assess transferrin saturation. The transferrin saturation is the ratio of the serum iron concentration and the total iron-binding capacity, expressed as a percentage. A positive change from baseline indicates transferrin saturation increased.

    Time frame: Baseline; Day 29

  14. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    An Adverse Event (AE) was defined as any untoward medical occurrence, signs, symptoms, disease, or laboratory or physiological observations occurring in a participant administered with drug, regardless of a causal relationship with that treatment or usage. This also included all suspected adverse medication reactions, reactions from medication overdose, abuse, withdrawal, sensitivity, toxicity, unrelated illnesses, including worsening a pre-existing condition, injury, or accidents. Serious Adverse Events (SAEs) was defined as any life-threatening condition; hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect; or death.

    Time frame: Up to 2 weeks post 28 days of treatment

  15. Number of Participants With Clinically Significant Changes From Baseline in Laboratory Parameter Values

    Parameters assessed for laboratory values included hematology, chemistry, urinalysis, and coagulation. The investigator was responsible for reviewing laboratory results for clinically significant changes.

    Time frame: Up to 2 weeks post 28 days of treatment

  16. Number of Participants With Clinically Significant Changes From Baseline in Vital Sign Values

    Parameters assessed for vital signs included sitting (at rest for a minimum of 5 minutes) heart rate, respiratory rate, body temperature, and blood pressure. The investigator was responsible for reviewing laboratory results for clinically significant changes.

    Time frame: Up to 2 weeks post 28 days of treatment

  17. Number of Participants With Clinically Abnormal 12-Lead Electrocardiogram (ECG) Findings

    A standard 12-lead ECG was performed following dosing in a supine position for approximately 10 minutes. ECGs were taken prior to blood draws when possible. The investigator was responsible for reviewing laboratory results for clinical significance.

    Time frame: Up to 2 weeks post 28 days of treatment

  18. Mean Change From Baseline in PR Interval, QT Interval, QRS Interval, and QT Corrected (QTc) Interval

    A standard 12-lead ECG was performed following dosing in a supine position for approximately 10 minutes. ECGs were taken prior to blood draws when possible. The parameters evaluated from the participant ECG trace included PR interval, QT interval, QRS interval, and QTc (corrected).

    Time frame: Up to 2 weeks post 28 days of treatment

  19. Mean Trough Concentrations of Vadadustat at Day 8, 15, 22 and 29

    Serum samples were collected from the participants at the defined time points. Trough concentration was defined as the concentration of drug in the blood immediately before the next dose is administered. Trough concentration was calculated using the validated liquid chromatography-mass spectrometry (LC-MS) and liquid chromatography-tandem mass spectrometry (LC-MS/MS) method

    Time frame: Pre-dose at Day 8, 15, 22 and 29

07

Results

Posted Jul 1, 2022
Limitations and caveats
This pilot study planned to include 15 participants with either Stage 3 or 4 CKD, with no minimum or maximum enrollment target for either stage; however, because of slow enrollment the Sponsor terminated the study early after only 10 participants had enrolled. The overall status of the study was considered as completed since 10 participants received Vadadustat and all 10 participants completed the study per protocol.

Participant flow

Participant flow — Overall Study
MilestoneVadadustat
Started10
Completed10
Not completed0

Outcome measures

PrimaryMean Change From Baseline in Hemoglobin (Hgb) on Day 29

Blood samples were collected to assess Hgb. Baseline Hgb was defined as the average of the 2 samples obtained prior to dosing (Pre-Baseline and Baseline). A positive change from baseline indicates that hemoglobin concentration increased.

Time frame:
Baseline; Day 29
Reported as:
Mean · Grams per decilitre (g/dL)
Mean Change From Baseline in Hemoglobin (Hgb) on Day 29
Grams per decilitre (g/dL)Vadadustat
Baseline9.91 ± 0.63
Change from Baseline on Day 290.63 ± 0.46
Statistical analysis
  • Vadadustat · Wilcoxon signed rank test · p = 0.0020
SecondaryMean Change From Baseline in Hematocrit on Day 29

Blood samples were collected to assess hematocrit. A positive change from baseline indicates hematocrit concentration increased.

Time frame:
Baseline; Day 29
Reported as:
Mean · Percentage of red blood cells in blood
Mean Change From Baseline in Hematocrit on Day 29
Percentage of red blood cells in bloodVadadustat
Baseline30.43 ± 2.69
Change from Baseline on Day 291.62 ± 1.71
Statistical analysis
  • Vadadustat · Wilcoxon signed rank test · p = =0.0156
SecondaryMean Change From Baseline in Total Red Blood Cell (RBC) Count on Day 29

Blood samples were collected to assess RBC count. Baseline RBC count was defined as the average of the 2 samples obtained prior to dosing (Pre-Baseline and Baseline). A positive change from baseline indicates RBC count increased.

Time frame:
Baseline; Day 29
Reported as:
Mean · Million cells per cubic millimeter
Mean Change From Baseline in Total Red Blood Cell (RBC) Count on Day 29
Million cells per cubic millimeterVadadustat
Baseline3.313 ± 0.389
Change from Baseline on Day 290.167 ± 0.170
Statistical analysis
  • Vadadustat · Wilcoxon signed rank test · p = 0.0098
SecondaryMean Change From Baseline in Absolute Reticulocyte Count on Day 29

Blood samples were collected to assess reticulocyte count. Baseline absolute reticulocyte count was defined as the average of the 3 reticulocyte counts obtained prior to dosing (Screening, Pre- Baseline, and Baseline). A positive change from baseline indicates absolute reticulocyte count increased.

Time frame:
Baseline; Day 29
Reported as:
Mean · Cells per Microlitre
Mean Change From Baseline in Absolute Reticulocyte Count on Day 29
Cells per MicrolitreVadadustat
Baseline51076.00 ± 24975.76
Change from Baseline on Day 2918647.00 ± 18289.84
Statistical analysis
  • Vadadustat · Wilcoxon signed rank test · p = =0.0195
SecondaryMean Change From Baseline in Reticulocyte Hemoglobin (Hgb) Content on Day 29

Blood samples were collected to assess reticulocyte Hgb. Baseline Hgb was defined as the average of the 2 samples obtained prior to dosing (Pre-Baseline and Baseline). A positive change from baseline indicates reticulocyte Hgb content increased.

Time frame:
Baseline; Day 29
Reported as:
Mean · Picograms
Mean Change From Baseline in Reticulocyte Hemoglobin (Hgb) Content on Day 29
PicogramsVadadustat
Baseline31.49 ± 2.44
Change from Baseline on Day 290.13 ± 0.84
Statistical analysis
  • Vadadustat · Wilcoxon signed rank test · p = =0.8262
SecondaryNumber of Participants With Absolute Change From Baseline in Hemoglobin (Hgb) at Day 29

Blood samples were collected to assess Hgb. Baseline Hgb was defined as the average of the 2 samples obtained prior to dosing (Pre-Baseline and Baseline).

Time frame:
Day 29
Reported as:
Count of participants · Participants
Number of Participants With Absolute Change From Baseline in Hemoglobin (Hgb) at Day 29
ParticipantsVadadustat
Change from baseline ≥ 0.4 grams per decilitre6
Change from baseline ≥ 0.6 grams per decilitre5
Change from baseline ≥ 0.8 grams per decilitre3
Change from baseline ≥ 1.0 grams per decilitre2
SecondaryNumber of Participants With the Percentage Change From Baseline in Hemoglobin (Hgb) at Day 29

Blood samples were collected to assess Hgb. Baseline Hgb was defined as the average of the 2 samples obtained prior to dosing (Pre-Baseline and Baseline).

Time frame:
Day 29
Reported as:
Count of participants · Participants
Number of Participants With the Percentage Change From Baseline in Hemoglobin (Hgb) at Day 29
ParticipantsVadadustat
Percent change from Baseline ≥ 5.0%5
Percent change from Baseline ≥ 7.5%3
Percent change from Baseline ≥ 10.0%3
SecondaryNumber of Participants With Percentage Change From Baseline in Hematocrit at Day 29

Blood samples were collected to assess hematocrit.

Time frame:
Day 29
Reported as:
Count of participants · Participants
Number of Participants With Percentage Change From Baseline in Hematocrit at Day 29
ParticipantsVadadustat
Percent change from Baseline ≥ 5.0%6
Percent change from Baseline ≥ 7.5%2
Percent change from Baseline ≥ 10.0%2
SecondaryNumber of Participants With Percentage Change From Baseline in Red Blood Cell (RBC) Count at Day 29

Blood samples were collected to assess RBC count. Baseline RBC count was defined as the average of the 2 samples obtained prior to dosing (Pre-Baseline and Baseline).

Time frame:
Day 29
Reported as:
Count of participants · Participants
Number of Participants With Percentage Change From Baseline in Red Blood Cell (RBC) Count at Day 29
ParticipantsVadadustat
Percent change from Baseline ≥ 5.0%5
Percent change from Baseline ≥ 7.5%3
Percent change from Baseline ≥ 10.0%3
SecondaryNumber of Participants With Change From Baseline in Absolute Reticulocyte Count at Day 29

Blood samples were collected to assess reticulocyte count. Baseline absolute reticulocyte count was defined as the average of the 3 reticulocyte counts obtained prior to dosing (Screening, Pre- Baseline, and Baseline).

Time frame:
Day 29
Reported as:
Count of participants · Participants
Number of Participants With Change From Baseline in Absolute Reticulocyte Count at Day 29
ParticipantsVadadustat
Change from Baseline ≥ 6000 cells per microlitre8
Change from Baseline ≥ 12000 cells per microlitre7
Change from Baseline ≥ 18000 cells per microlitre6
SecondaryChange From Baseline in Ferritin on Day 29

Blood samples were collected to assess ferritin. A positive change from baseline indicates ferritin content increased.

Time frame:
Baseline; Day 29
Reported as:
Mean · Nanograms per millilitre
Change From Baseline in Ferritin on Day 29
Nanograms per millilitreVadadustat
Baseline324.0 ± 199.2
Change from Baseline on Day 29-52.3 ± 36.6
Statistical analysis
  • Vadadustat · Wilcoxon signed rank test · p = =0.0020
SecondaryChange From Baseline in Iron on Day 29

Blood samples were collected to assess iron. A positive change from baseline indicates iron content increased.

Time frame:
Baseline; Day 29
Reported as:
Mean · Micrograms per decilitre
Change From Baseline in Iron on Day 29
Micrograms per decilitreVadadustat
Baseline69.4 ± 18.4
Change from Baseline on Day 29-8.2 ± 20.3
Statistical analysis
  • Vadadustat · Wilcoxon signed rank test · p = =0.2383
SecondaryChange From Baseline in Total Iron Binding Capacity on Day 29

Blood samples were collected to assess total iron binding capacity. A positive change from baseline indicates total iron binding capacity increased.

Time frame:
Baseline; Day 29
Reported as:
Mean · Micrograms per decilitre
Change From Baseline in Total Iron Binding Capacity on Day 29
Micrograms per decilitreVadadustat
Baseline266.4 ± 56.4
Change from Baseline on Day 2943.4 ± 34.8
Statistical analysis
  • Vadadustat · Wilcoxon signed rank test · p = =0.0039
SecondaryChange From Baseline in Transferrin Saturation on Day 29

Blood samples were collected to assess transferrin saturation. The transferrin saturation is the ratio of the serum iron concentration and the total iron-binding capacity, expressed as a percentage. A positive change from baseline indicates transferrin saturation increased.

Time frame:
Baseline; Day 29
Reported as:
Mean · Percentage
Change From Baseline in Transferrin Saturation on Day 29
PercentageVadadustat
Baseline26.1 ± 6.3
Change from Baseline on Day 29-6.4 ± 5.4
Statistical analysis
  • Vadadustat · Wilcoxon signed rank test · p = =0.0039
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs)

An Adverse Event (AE) was defined as any untoward medical occurrence, signs, symptoms, disease, or laboratory or physiological observations occurring in a participant administered with drug, regardless of a causal relationship with that treatment or usage. This also included all suspected adverse medication reactions, reactions from medication overdose, abuse, withdrawal, sensitivity, toxicity, unrelated illnesses, including worsening a pre-existing condition, injury, or accidents. Serious Adverse Events (SAEs) was defined as any life-threatening condition; hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect; or death.

Time frame:
Up to 2 weeks post 28 days of treatment
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsVadadustat
TEAEs5
SAEs0
Deaths0
SecondaryNumber of Participants With Clinically Significant Changes From Baseline in Laboratory Parameter Values

Parameters assessed for laboratory values included hematology, chemistry, urinalysis, and coagulation. The investigator was responsible for reviewing laboratory results for clinically significant changes.

Time frame:
Up to 2 weeks post 28 days of treatment
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes From Baseline in Laboratory Parameter Values
ParticipantsVadadustat
Number of Participants With Clinically Significant Changes From Baseline in Laboratory Parameter Values0
SecondaryNumber of Participants With Clinically Significant Changes From Baseline in Vital Sign Values

Parameters assessed for vital signs included sitting (at rest for a minimum of 5 minutes) heart rate, respiratory rate, body temperature, and blood pressure. The investigator was responsible for reviewing laboratory results for clinically significant changes.

Time frame:
Up to 2 weeks post 28 days of treatment
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes From Baseline in Vital Sign Values
ParticipantsVadadustat
Number of Participants With Clinically Significant Changes From Baseline in Vital Sign Values0
SecondaryNumber of Participants With Clinically Abnormal 12-Lead Electrocardiogram (ECG) Findings

A standard 12-lead ECG was performed following dosing in a supine position for approximately 10 minutes. ECGs were taken prior to blood draws when possible. The investigator was responsible for reviewing laboratory results for clinical significance.

Time frame:
Up to 2 weeks post 28 days of treatment
Reported as:
Count of participants · Participants
Number of Participants With Clinically Abnormal 12-Lead Electrocardiogram (ECG) Findings
ParticipantsVadadustat
Number of Participants With Clinically Abnormal 12-Lead Electrocardiogram (ECG) Findings0
SecondaryMean Change From Baseline in PR Interval, QT Interval, QRS Interval, and QT Corrected (QTc) Interval

A standard 12-lead ECG was performed following dosing in a supine position for approximately 10 minutes. ECGs were taken prior to blood draws when possible. The parameters evaluated from the participant ECG trace included PR interval, QT interval, QRS interval, and QTc (corrected).

Time frame:
Up to 2 weeks post 28 days of treatment
Reported as:
Mean · Milliseconds
Mean Change From Baseline in PR Interval, QT Interval, QRS Interval, and QT Corrected (QTc) Interval
MillisecondsVadadustat
Baseline PR Interval183.2 ± 42.6
Change from Baseline PR Interval-4.4 ± 18.1
Baseline QT Interval415.6 ± 45.7
Change from Baseline QT Interval1.4 ± 20.3
Baseline QRS Interval95.4 ± 21.4
Change from Baseline QRS Interval3.4 ± 6.7
Baseline QTC Interval429.9 ± 30.5
Change from Baseline QTC Interval4.1 ± 8.3
SecondaryMean Trough Concentrations of Vadadustat at Day 8, 15, 22 and 29

Serum samples were collected from the participants at the defined time points. Trough concentration was defined as the concentration of drug in the blood immediately before the next dose is administered. Trough concentration was calculated using the validated liquid chromatography-mass spectrometry (LC-MS) and liquid chromatography-tandem mass spectrometry (LC-MS/MS) method

Time frame:
Pre-dose at Day 8, 15, 22 and 29
Reported as:
Mean · nanograms per millilitre
Mean Trough Concentrations of Vadadustat at Day 8, 15, 22 and 29
nanograms per millilitreVadadustat
Day 83260.6 ± 2763.8
Day 153826.3 ± 2537.5
Day 223667.4 ± 1933.4
Day 295622.4 ± 5385.4

Adverse events

Collected over Up to 2 weeks post 28 days of treatment. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vadadustat0/10 (0%)0/10 (0%)5/10 (50%)
Most frequent other events
Showing 10 of 13
Most frequent other events
EventVadadustat
DiarrhoeaGastrointestinal disorders2/10
ConstipationGastrointestinal disorders1/10
DyspepsiaGastrointestinal disorders1/10
NauseaGastrointestinal disorders1/10
ChillsGeneral disorders1/10
FatigueGeneral disorders1/10
Decreased appetiteMetabolism and nutrition disorders1/10
HyperkalaemiaMetabolism and nutrition disorders1/10
Muscle spasmsMusculoskeletal and connective tissue disorders1/10
DizzinessNervous system disorders1/10

Baseline characteristics

Full Analysis Set: All participants who received at least 1 dose of study medication. Per the protocol, all results data are summarized as a single treatment arm (i.e., all participants receiving Vadadustat); no separate analysis was performed to report results by disease state.

Age, Continuous
Age, Continuous(years)Vadadustat
Mean60.1 ± 11.8
Sex: Female, Male
Sex: Female, Male(Participants)Vadadustat
Female5
Male5
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Vadadustat
Hispanic or Latino1
Not Hispanic or Latino9
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Vadadustat
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American5
White4
More than one race0
Unknown or Not Reported1
Kidney disease stage
Kidney disease stage(Participants)Vadadustat
Stage 36
Stage 44
08

Study locations

2 sites
  • Augusta, Georgia, United States
  • San Antonio, Texas, United States
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2010, a primary completion of Apr 2011 and a completion of May 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2022, 11 years 2 months after primary completion. A results delay was requested in Sep 2012.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2010
First posted
Nov 8, 2010
Start
Oct 21, 2010
Primary completionActual
Apr 13, 2011
CompletionActual
May 2011
Results delay requested
Sep 14, 2012
Results first posted
Jul 1, 2022
Last update
Jul 1, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01235936
Responsible party
Sponsor
First posted
Nov 8, 2010
Start date
Oct 21, 2010
Primary completion
Apr 13, 2011
Completion
May 2011
Results posted
Jul 1, 2022
Last update
Jul 1, 2022

Study contacts

Chief Medical Officer
study director · Akebia Therapeutics Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vadadustat

Start the discussion